OGM Adoption Opportunity Lineagen operates in neurodevelopmental diagnostics and offers OGM data services, suggesting a receptive market for expanding Optical Genome Mapping (OGM) offerings, especially alongside existing neurodevelopmental testing programs to broaden service lines and revenue per client.

Hematologic Focus Recent press indicates Bionano Laboratories launched and expanded OGM-based tests for hematological malignancies, signaling a growing demand in blood cancer diagnostics that Lineagen could align with by highlighting OGM capabilities to hospital networks and pathology departments.

Category I CPT Momentum The introduction of a Category I CPT code for OGM use creates clearer reimbursement pathways, presenting an opportunity to target payer negotiations and GPOs with Lineagen’s OGM services as a reimbursable, scalable option.

Mid-market Entry With 11-50 employees and revenue in the low single digits, there is potential to position Lineagen as a nimble partner for regional hospitals and independent labs seeking advanced, cost-effective OGM solutions without large enterprise commitments.

Strategic Partnerships Leverage Lineagen’s integrated neurodevelopmental focus alongside OGM offerings to pursue collaborations with pediatric hospitals, academic medical centers, and reference labs, expanding footprint through joint projects, LDTs, and data services contracts.